Becton Dickinson's revenues drop 1.8% in Q4

Becton, Dickinson and Co.'s revenues fell from $4.85 billion in last year's fourth quarter to $4.76 billion, equal to about a 1.8 percent decrease in sales, the devicemaker said Nov. 10. 

During its latest fiscal year, BD reported its revenues dipping 1.4 percent as it made $19.1 billion in 2021 and raked in $18.9 billion in 2022. 

The company attributed part of the loss to less demand for its COVID-19 diagnostic tests. Among its three main segments — medical, life sciences and interventional — BD's life sciences sales fell 16.3 percent compared to last year's figures because of dwindling demand for COVID-19 tests.  

BD whittled its 2023 projected earnings for the tests to be between $125 million and $175 million — a sharp dropoff from 2022's sales, which were $511 million.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars